Photoreceptors burn through more energy per gram than almost any other cell in the human body, and by middle age their mitochondria are visibly failing. A new narrative review published in Ophthalmol Ther in August 2026 lays out a case that’s been building quietly for years: specific wavelengths of red and near-infrared light can reach into that mitochondrial machinery and partially reverse the decline, with implications for everything from ordinary age-related vision loss to macular degeneration and diabetic eye disease.
Why the retina is an unusually good target
The retina consumes oxygen at a rate that rivals the heart, and its photoreceptors are packed with mitochondria to keep up with the constant demand of converting light into electrical signals. That density makes the retina one of the most metabolically expensive tissues in the body, and also one of the most vulnerable to mitochondrial decline with age.
Cytochrome c oxidase, the enzyme complex at the final step of the mitochondrial electron transport chain, happens to absorb light strongly in the red and near-infrared range, roughly 630 to 900 nanometers. When photons in that window hit the enzyme, they appear to boost its activity, increasing ATP output and reducing the buildup of reactive oxygen species that drive cellular aging. That’s the mechanistic backbone of photobiomodulation, and it’s why the eye, more than almost any other organ, responds measurably to it.
The research that started this conversation
Much of the foundational human data traces back to work led by Glen Jeffery at University College London, whose team showed that a few minutes of daily exposure to 670-nanometer light improved rod and cone sensitivity in adults over 40, with the biggest gains showing up in the aging-prone rod pathway. The effect size was notable: in one trial, short daily sessions improved dark-adapted retinal sensitivity by around 20% in participants in their 40s to 70s, essentially knocking years off the eye’s functional age on that test.
The new Ophthalmol Ther review situates that line of research alongside a broader, more clinically oriented body of work, including trials on the Valeda Light Delivery System from LumiThera, which combines 590, 660, and 850-nanometer wavelengths and has been tested specifically in dry age-related macular degeneration through the LIGHTSITE trial series. Those studies reported improvements in visual acuity and reductions in drusen volume, the fatty deposits that accumulate under the retina and mark disease progression, though the review is careful to note that effect durability and long-term safety data are still catching up to the enthusiasm.
Where the evidence is strongest, and where it thins out
Dry age-related macular degeneration has the most developed evidence base, in part because it’s a condition defined by mitochondrial and metabolic dysfunction in the retinal pigment epithelium, exactly the kind of damage photobiomodulation is theorized to address. Diabetic retinopathy is the next most studied application, where near-infrared exposure has shown early signals of reducing microvascular damage and inflammatory markers in small trials, though the review flags that sample sizes remain too small for firm conclusions.
Ordinary age-related visual decline, the kind that hits nearly everyone by their 50s without qualifying as disease, has the cleanest mechanistic story but the least commercial attention. Glaucoma and ocular surface conditions like dry eye appear in the review as emerging areas with promising cell-culture and animal data, but limited human trial evidence so far.
A narrative review isn’t a green light
Worth noting: this is a narrative review, not a systematic review or meta-analysis, meaning the authors synthesized existing trial data and mechanistic studies rather than pooling raw results under strict statistical criteria. That format is well suited to a fast-moving field where trial designs still vary widely, but it also means the conclusions lean more on expert interpretation than on a single aggregated effect size.
The authors are upfront about this, framing photobiomodulation as a promising adjunct worth larger dedicated trials rather than a therapy ready for blanket clinical adoption. Mitochondrial decline itself isn’t unique to the eye, it shows up in skin, muscle, and brain tissue as people age, which is part of why photobiomodulation research has expanded into so many unrelated fields at once. What makes the retina distinct is how directly its function can be measured, researchers can quantify dark-adapted sensitivity or visual acuity with a precision that’s hard to match when studying, say, joint inflammation or skin elasticity.
Dose and timing matter more than most people assume
One of the review’s more practical takeaways is that photobiomodulation follows a biphasic dose response, meaning more light isn’t better past a certain point. Too little energy does nothing, and too much can tip into pro-oxidant territory, actually increasing cellular stress instead of relieving it, a phenomenon researchers call the Arndt-Schulz law applied to light medicine.
That’s a meaningfully different situation from red light therapy aimed at skin or joints, where a wider margin of error tends to be more forgivable. Clinical ocular protocols use tightly controlled irradiance, wavelength, and exposure duration, delivered directly to the eye rather than diffused across a body panel, which is a large part of why devices like Valeda require in-office administration rather than home use.
What this means for people already using red light panels at home
General-purpose red light panels, the kind reviewed in Athletic Insight’s look at the Hooga Pro panel or the Joovv Solo 3.0, are built and dosed for skin and muscle tissue, not for direct ocular exposure. None of the devices marketed for recovery, skin, or joint use, including those covered in Athletic Insight’s guides to red light therapy for knee pain and red light therapy for weight loss, have been validated for direct eye exposure at the intensities studied in these ophthalmology trials.
The review’s authors are explicit that the ocular applications under study use purpose-built medical devices with specific irradiance limits, and that unsupervised high-intensity exposure to the eyes carries real risk of thermal or photochemical retinal injury. Anyone tempted to stare into a home panel on the theory that more light means more benefit is working from the wrong end of the dose curve entirely.
What comes next
The review calls for larger, longer randomized trials with standardized wavelength and dosing protocols, something the field has lacked as different research groups and device makers have each used slightly different combinations of wavelengths and exposure times. Regulatory clarity is also lagging: Valeda has earned conditional approvals in several markets for dry AMD, but broader indications remain investigational.
What’s changed is the tone of the conversation. A decade ago, shining light on the eye to slow aging sounded like the kind of claim that belonged nowhere near a peer-reviewed ophthalmology journal, and now it’s the subject of a formal narrative review synthesizing multiple clinical trial programs. The mitochondrial mechanism is well established, the early human data is consistent enough to take seriously, and the next few years of larger trials will determine whether photobiomodulation earns a permanent place in eye care or ends up as a promising idea that never scaled past the lab.
